TherapeuticsMD (TXMD) Raw Materials (2012 - 2022)

TherapeuticsMD (TXMD) has reported Raw Materials for 11 consecutive years, with $1.9 million the latest figure, recorded in Q3 2022.

• For the quarter ending Q3 2022, Raw Materials fell 44.19% year-over-year to $1.9 million; the trailing twelve-month figure through Sep 2022 stood at $1.9 million (down 44.19% YoY), and the FY2021 full-year result was $3.0 million, down 18.84% from the prior year.
• Raw Materials climbed to $1.9 million in Q3 2022 per TXMD's latest filing, from $434000.0 in the prior quarter.
• Across five years, Raw Materials topped out at $5.7 million in Q4 2019 and bottomed at $19400.0 in Q4 2018.
• Historically, Raw Materials has averaged $3.0 million across 5 years, with a median of $3.6 million in 2020.
• The sharpest annual moves came in 2019 and 2022: Raw Materials surged 29290.45% in 2019, then sank 90.43% in 2022.
• Over 5 years, Raw Materials stood at $19400.0 in 2018, then soared by 29290.45% to $5.7 million in 2019, then plunged by 34.27% to $3.7 million in 2020, then retreated by 18.84% to $3.0 million in 2021, then tumbled by 36.03% to $1.9 million in 2022.
• According to Business Quant data, Raw Materials over the past three periods registered $1.9 million, $434000.0, and $4.4 million for Q3 2022, Q2 2022, and Q1 2022 respectively.